MedTrace Logo

Metabolism of Chlordiazepoxide in the Treatment of Alcohol Withdrawal Symptoms

NCT05563350 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 26

Last updated 2024-05-07

No results posted yet for this study

Summary

The aim of this study is to elucidate if CYP-phenotypes, variations in CYP-genotypes and dose of chlordiazepoxide is correlated to chlordiazepoxide plasma concentrations in patients admitted to Intensive Care or High Dependency Units due to either respiratory insufficiency and/or agitation while treated for alcohol withdrawal symptoms.

Conditions

  • Alcohol Withdrawal

Interventions

DIAGNOSTIC_TEST

Blood samples

p-chlordiazepoxide and metabolites, p-omeprazole and metabolites, p-midazolam and metabolites, CYP3A4 and CYP2C19 genotyping

Sponsors & Collaborators

  • University Hospital Bispebjerg and Frederiksberg

    lead OTHER

Principal Investigators

  • Nanna Reiter, MD · Bispebjerg and Frederiksberg Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-29
Primary Completion
2023-06-11
Completion
2023-07-01
FDA Drug
Yes

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05563350 on ClinicalTrials.gov